Halozyme Therapeutics Inc (HALO)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 115,850 | 154,318 | 187,864 | 164,627 | 118,370 | 274,227 | 221,165 | 96,383 | 234,195 | 147,159 | 90,932 | 117,835 | 118,719 | 491,683 | 446,966 | 499,450 | 147,703 | 65,741 | 133,606 | 104,820 |
| Short-term investments | US$ in thousands | 480,224 | 511,988 | 341,166 | 298,824 | 217,630 | 209,055 | 127,110 | 179,225 | 128,599 | 118,425 | 118,428 | 668,305 | 622,203 | 324,237 | 308,343 | 264,856 | 220,310 | 280,965 | 251,840 | 263,363 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 139,100 | 108,815 | 133,360 | 131,639 | 112,494 | 115,185 | 116,393 | 91,919 | 130,789 | 109,384 | 199,512 | 111,691 | 117,147 | 113,153 | 114,251 | 107,421 | 421,385 | 26,976 | 26,073 | 42,002 |
| Quick ratio | 4.29 | 6.12 | 3.97 | 3.52 | 2.99 | 4.20 | 2.99 | 3.00 | 2.77 | 2.43 | 1.05 | 7.04 | 6.32 | 7.21 | 6.61 | 7.12 | 0.87 | 12.85 | 14.78 | 8.77 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($115,850K
+ $480,224K
+ $—K)
÷ $139,100K
= 4.29
The quick ratio of Halozyme Therapeutics Inc has shown fluctuations over the reported periods. The quick ratio measures the company's ability to meet its short-term obligations with its most liquid assets. A higher quick ratio indicates a stronger ability to cover short-term liabilities.
Based on the data provided:
- The quick ratio increased from 8.77 on March 31, 2020, to a peak of 14.78 on June 30, 2020, demonstrating a very strong liquidity position during that period.
- However, the quick ratio declined significantly to 0.87 on December 31, 2020, which may indicate potential liquidity challenges or a shift in the company's asset composition.
- Subsequently, the quick ratio showed some recovery, reaching 7.21 on September 30, 2021, before fluctuating around the range of 6 to 7 in the following quarters.
It is important to note that a quick ratio of less than 1 may raise concerns about the company's ability to meet its short-term obligations. Overall, the analysis suggests that Halozyme Therapeutics Inc experienced fluctuations in its liquidity position, with varying levels of ability to cover short-term liabilities during the reported periods.
Peer comparison
Dec 31, 2024